Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Leukemia, Myeloid, Acute 54Myelodysplastic Syndromes 47Leukemia 36Lymphoma, Non-Hodgkin 34Lymphoma 32Breast Neoplasms 29Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Central Nervous System Neoplasms 21Hodgkin Disease 19Hematologic Neoplasms 19Neuroblastoma 18Leukemia, Lymphocytic, Chronic, B-Cell 17Burkitt Lymphoma 15Multiple Myeloma 14Medulloblastoma 14Leukemia, Myeloid, Accelerated Phase 13Leukemia, Biphenotypic, Acute 13Brain Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Blast Crisis 12Graft vs Host Disease 11Congenital Abnormalities 11Myeloproliferative Disorders 10Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Follicular 10Dendritic Cell Sarcoma, Interdigitating 10Astrocytoma 10Anemia, Refractory, with Excess of Blasts 10Recurrence 9

Interventions

Cyclophosphamide 8dinutuximab 7Magnetic Resonance Spectroscopy 7Topotecan 6Doxorubicin 6sargramostim 5Vincristine 5Stem Cell Transplantation 5Radiation 5Platinum 5Melphalan 5Isotretinoin 5Colony-Stimulating Factors 5Cisplatin 5Biopsy 51,2-diaminocyclohexaneplatinum II citrate 5Temozolomide 4Specimen Handling 4Irinotecan 4Etoposide 4Congresses as Topic 4Carboplatin 4Thiotepa 3Busulfan 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2temsirolimus 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Ganglioneuroblastoma × Thiotepa × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡